Nexalin Technology Files 8-K
Ticker: NXL · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1527352
Sentiment: neutral
Topics: 8-K, filing, corporate-event
Related Tickers: NXL
TL;DR
Nexalin Tech filed an 8-K on June 13th, expect more details soon.
AI Summary
Nexalin Technology, Inc. filed an 8-K on June 18, 2024, reporting an event that occurred on June 13, 2024. The filing pertains to "Other Events" and "Financial Statements and Exhibits." Specific details regarding the nature of these events or exhibits are not provided in the excerpt.
Why It Matters
This 8-K filing indicates a material event or change for Nexalin Technology, Inc., requiring disclosure to investors.
Risk Assessment
Risk Level: medium — 8-K filings often signal significant corporate events, but the lack of specific details in this excerpt makes it difficult to assess the immediate impact.
Key Players & Entities
- Nexalin Technology, Inc. (company) — Registrant
- June 13, 2024 (date) — Earliest event reported
- June 18, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 1776 Yorktown, Suite 550 Houston, TX 77056 (address) — Business address
FAQ
What specific event triggered this 8-K filing for Nexalin Technology, Inc. on June 13, 2024?
The provided excerpt does not specify the exact event that triggered the 8-K filing, only that it falls under 'Other Events' and 'Financial Statements and Exhibits'.
What is the nature of the 'Financial Statements and Exhibits' mentioned in the filing?
The excerpt does not detail the content of the financial statements or exhibits filed.
When was Nexalin Technology, Inc. incorporated, and in which state?
Nexalin Technology, Inc. was incorporated in Delaware.
What is the business address and phone number for Nexalin Technology, Inc.?
The business address is 1776 Yorktown, Suite 550, Houston, TX 77056, and the phone number is (832) 260-0222.
What is the SEC file number for Nexalin Technology, Inc.?
The SEC file number for Nexalin Technology, Inc. is 001-41507.
Filing Stats: 465 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-06-18 17:02:05
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share NXL The Nasdaq Stock Mark
Filing Documents
- nexalintech_8k.htm (8-K) — 40KB
- nexalintech_ex99-1.htm (EX-99.1) — 7KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001829126-24-004310.txt ( ) — 276KB
- nxl-20240613.xsd (EX-101.SCH) — 4KB
- nxl-20240613_def.xml (EX-101.DEF) — 26KB
- nxl-20240613_lab.xml (EX-101.LAB) — 36KB
- nxl-20240613_pre.xml (EX-101.PRE) — 25KB
- nexalintech_8k_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On June 13, 2024, Nexalin Technology, Inc. (the " Company ") issued a press release announcing that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device has been granted regulatory approval by the Brazilian Health Regulatory Agency, a regulatory body of the Brazilian government responsible for approving new drugs and medical devices. A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release Dated June 13, 2024 104 Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report on form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. NEXALIN TECHNOLOGY, INC. By: /s/ Mark White Mark White Chief Executive Officer Dated: June 18, 2024 2